176
Views
13
CrossRef citations to date
0
Altmetric
Original Research

EGFR mutational status in penile cancer

, MD PhD, , , , , , , , , , & show all
Pages 501-505 | Published online: 22 Mar 2013

Bibliography

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
  • Sonpavde G, Pagliaro LC, Buonerba C, Penile cancer: current therapy and future directions. Ann Oncol 2013; Epub ahead of print
  • Verhoeven RH, Janssen-Heijnen ML, Saum KU, Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. Eur J Cancer 2012; Epub ahead of print
  • Di Lorenzo G, Buonerba C, Federico P, Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 2012;110(11 Pt B):E661-6
  • Di Lorenzo G, Federico P, Buonerba C, Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011;60:1280-4
  • Carthon BC, Pettaway C, Pagliaro LC. Epidermal growth factor receptor (EGFR) targeted therapy in advanced metastatic squamous cell carcinoma (AMSCC) of the penis: updates and molecular analyses. J Clin Oncol 2010;28(Suppl):abstr e15022
  • Rescigno P, Matano E, Raimondo L, Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. Anticancer Drugs 2012;23:573-7
  • Necchi A, Nicolai N, Colecchia M, Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2013;31:288-9
  • Lavens N, Gupta R, Wood LA. EGFR overexpression in squamous cell carcinoma of the penis. Curr Oncol 2010;17:4-6
  • Stankiewicz E, Prowse DM, Ng M, Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS One 2011;6:e17517
  • Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 2012;13:287-97
  • Shigematsu H, Lin L, Takahashi T, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
  • Seshacharyulu P, Ponnusamy MP, Haridas D, Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:15-31
  • Shepherd FA, Rodrigues Pereira J, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
  • Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
  • Xu Y, Sheng L, Mao W. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action. Oncol Lett 2013;5:19-24
  • Peereboom DM, Ahluwalia MS, Ye X, NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 2013; Epub ahead of print
  • McMillen E, Ye F, Li G, Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res 2010;36:531-7
  • Andersson P, Kolaric A, Windahl T, PIK3CA, HRAS and KRAS gene mutations in human penile cancer. J Urol 2008;179:2030-4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.